For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.

Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery & Innovation, she’s also a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She also spoke about this topic at the 2026 World Conference on Lung Cancer.

What does current evidence tell us about subcutaneous lipoprotein(a)-lowering therapies? Find out as Dr. M. Melih Dogan shares findings from a recent meta-analysis examining their efficacy, safety, and effects on key lipid parameters, along with the limitations that remain as larger clinical trials continue. He's a Postdoctoral Researcher at East Carolina University Heart Institute, and he spoke about this topic at the 2026 European Society of Cardiology Congress in Munich.

As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He’s a board-certified hematologist and medical oncologist at Emory Winship Cancer Institute in Atlanta, and he spoke about this topic at the 2026 Society of Hematologic Oncology Annual Meeting.

How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.

Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of combining modalities to improve positive predictive value, and next steps toward prospective deployment in clinical practice.

Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify elevated risk earlier. Dr. Bairey Merz is the Director of the Barbra Streisand Women’s Health Center, the Linda Joy Pollin Women’s Heart Health Program, and the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Smidt Heart Institute in Beverly Hills, California. She also spoke about this topic at the 2026 European Society of Cardiology Congress.